FARGO, N.D.

北达科他州法戈

,

，

Oct. 12, 2026

2026年10月12日

/PRNewswire/ -- Sharp Biomedical, a medical device company pioneering accessible, safe, and manual procedures for outpatient pain clinics, announced today the successful closing of its pre-seed funding round. The round was led by gener8tor 1889, a North Dakota venture capital fund, with participation from several physician angel investors..

/美通社/ -- 夏普生物医学公司（Sharp Biomedical）是一家致力于为门诊疼痛诊所提供可及、安全且手动操作的医疗器械公司，今日宣布其预种子轮融资已成功完成。本轮融资由北达科他州风险投资基金 gener8tor 1889 领投，多位医生天使投资人参与跟投。

Continue Reading

继续阅读

Dan Newman, Founder and CEO

丹·纽曼，创始人兼首席执行官

The new capital will fully fund the development and testing pathway necessary to bring Sharp Biomedical's first purpose-built toolset and implant system to market. Designed specifically to fit within the workflow of outpatient pain clinics, the technology provides a critical new option for early-to-mid-stage chronic pain patients..

新资本将全额资助开发和测试路径，以使夏普生物医学公司首款专用工具组和植入系统得以上市。该技术专为适应门诊疼痛诊所的工作流程而设计，为早期至中期慢性疼痛患者提供了一个关键的新选择。

Sharp Biomedical is pioneering a complementary path forward for the industry, firmly grounded in simple procedures. The company is developing elegant, safe, and entirely manual procedures designed to be completed seamlessly within outpatient facilities. This approach broadens patient access by shifting effective interventions directly into local clinics, all without requiring intensive capital expenditures or massive infrastructure overhauls..

Sharp Biomedical 正在为行业开创一条以简化操作为核心的互补性发展路径。该公司致力于开发优雅、安全且完全手动的操作流程，旨在门诊设施中无缝完成。这一方法通过将有效的干预措施直接下沉至本地诊所，扩大了患者的可及性，同时无需高昂的资本支出或大规模的基础设施改造。

'While the industry is rightfully focused on remarkable advancements in robotics and complex technologies for late-stage spinal care, we see a massive unmet need earlier in the care continuum,' said Dan Newman, Founder and CEO of Sharp Biomedical. 'We are thrilled to partner with gener8tor 1889 and our angel investors to finalize our development.

“尽管行业正合理地将重心放在脊柱护理后期阶段的机器人技术和复杂技术的显著进步上，但我们看到在护理连续体的早期阶段存在巨大的未满足需求，”Sharp Biomedical 的创始人兼首席执行官 Dan Newman 表示。“我们很高兴与 gener8tor 1889 以及我们的天使投资人合作，以完成我们的开发工作。”

This pre-seed funding allows us to empower physicians with simple, safe, and reliable procedures—giving clinics advanced intervention capabilities without the burden of massive capital demands.'.

这笔种子前轮融资使我们能够为医生提供简单、安全且可靠的诊疗方案，让诊所无需承担巨额资本支出的负担，即可具备先进的介入治疗能力。

'Dan is an extremely impressive startup founder, and we have built a huge amount of conviction in him and the entire Sharp Biomedical team,' said Ben Stanley, Principal of gener8tor 1889. 'Their mission to democratize access to spine care by empowering outpatient clinics with fast, safe, and reliable toolsets is a breath of fresh air in a highly complex industry.

“Dan 是一位令人印象深刻的初创公司创始人，我们对他以及整个 Sharp Biomedical 团队建立了深厚的信心，” gener8tor 1889 的负责人 Ben Stanley 表示。“他们的使命是通过为门诊诊所提供快速、安全且可靠的工具集，推动脊柱护理服务的普及化，这在高度复杂的行业中犹如一股清新之风。”

We look forward to both the profound impact this technology will have on patient care, along with their continued commitment to growing the North Dakota biotech ecosystem.'.

我们期待这项技术对患者护理产生的深远影响，也期待他们继续致力于壮大北达科他州的生物技术生态系统。

The medical community is also recognizing the clinical potential of Sharp Biomedical's streamlined approach. 'I'm excited to partner with Sharp Biomedical as they fill a vital gap in the market,' said Dr. Danny Neuman, Interventional Pain Specialist, Medical Staff President at Ascentist Healthcare, and advisor to Sharp.

医疗界也日益认可夏普生物医学公司（Sharp Biomedical）精简方案的临床潜力。“我很高兴与夏普生物医学公司合作，因为他们填补了市场上一个至关重要的空白。”丹尼·纽曼博士表示，他是介入疼痛专科医生、阿森蒂斯特医疗保健（Ascentist Healthcare）的医务主任，同时也是夏普公司的顾问。

'What sets Sharp apart is their intelligent design process, rooted in true collaborative input from physicians to directly address real clinical needs. This partnership will allow us to intervene earlier in the care continuum and offer definitive relief right in the outpatient setting, and their talented team is exceptionally well-positioned to drive these advancements.'.

“Sharp 的与众不同之处在于其智能设计流程，该流程植根于与医师的真正协作输入，直接应对真实的临床需求。此次合作将使我们能够在医疗护理连续体中更早介入，并在门诊环境中提供确切的缓解方案，而他们才华横溢的团队在推动这些进步方面具备极佳的优势。”

With funding secured, Sharp Biomedical is aggressively moving forward with its rigorous testing protocols and physician input, positioning the company for its next regulatory milestones and the eventual commercial launch of its flagship device.

在资金到位后，夏普生物医学公司正积极推进其严格的测试方案并征求医师意见，为公司实现下一个监管里程碑及其旗舰设备的最终商业化上市奠定基础。

About Sharp Biomedical

关于夏普生物医学

Sharp Biomedical is a medical device company focused on creating novel, streamlined toolsets and implants for spinal care. By designing safe, manual procedures that can be performed in less operating time, Sharp Biomedical empowers outpatient pain clinics to treat early-to-mid-stage chronic pain, reducing the industry's reliance on large hospital infrastructure, robotics, and prolonged operating times..

Sharp Biomedical 是一家医疗器械公司，专注于为脊柱护理开发新颖、精简的工具套装和植入物。通过设计安全且可在更短手术时间内完成的手动操作程序，Sharp Biomedical 赋能门诊疼痛诊所治疗早中期慢性疼痛，从而减少行业对大型医院基础设施、机器人技术以及长时间手术的依赖。

About Gener8tor

关于 Gener8tor

gener8tor is a global venture firm and accelerator network that supports startups, founders, workers, employers, artists, and musicians across race, place, and gender. Gener8tor partners with companies, governments, universities, and nonprofits to operate programs in more than 41 communities across 22 states and two countries.

gener8tor 是一家全球性的风险投资公司和加速器网络，致力于支持跨越种族、地域和性别的初创企业、创始人、工作者、雇主、艺术家和音乐家。Gener8tor 与企业、政府、大学和非营利组织合作，在22个州和两个国家的41多个社区运营项目。

gener8tor 1889 is a Venture Capital fund focused on North Dakota startups operated by gener8tor..

gener8tor 1889 是一只由 gener8tor 运营、专注于北达科他州初创企业的风险投资基金。

SOURCE Sharp Biomedical

来源：夏普生物医学

21

二十一

%

百分之

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示